NCT06700083CompletedPhase 1
A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Subcutaneous Injections of SHR-6934 in Healthy Subjects: a Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Trial
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase Ⅰ clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part. A total of 88 healthy subjects were included.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 19 Nov 2024
- Start date
- 6 Jan 2025
- Primary completion date
- 10 May 2026
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
- Diseases
- Heart failure
- NCT number
- NCT06700083
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 72
- From 6 Jan 2025 to the primary completion date, 10 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of any clinically important disease or disorder;
- History of drug or other allergies, or who, in the judgement of the investigator, may be allergic to the study drug or any component of the study drug;
- Positive results of hepatitis B surface antigen, hepatitis C antibody, syphilis antibody and human immunodeficiency virus antibody.
Lab values
- Prior history of risk factors for Torsades de Pointes, such as unexplained syncope, definite long QT syndrome (including family history), heart failure, myocardial infarction, angina pectoris;
Other
- Systolic blood pressure (SBP)≥140 mmHg or \<90 mmHg, diastolic blood pressure (DBP) ≥90 mmHg or \<60 mmHg;
- Patients with orthostatic hypotension;
Who the study is looking for
- Understand the study procedures and methods, voluntarily participate in the study, comply with study requirements, and sign the written informed consent form (ICF);
- Male or female aged 18-60;
- Females must have a negative pregnancy test at the Screening Visit;
- Body mass index (BMI) between 19 and 28 kg/m2;
- Normal Electrocardiogram (ECG);
- Men and women of childbearing potential must agree to take effective contraceptive methods.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.